Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Cash Flow: 2013-2024

Historic Net Cash Flow for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$9.7 million.

  • Zevra Therapeutics' Net Cash Flow fell 56.37% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$621,000, marking a year-over-year decrease of 105.84%. This contributed to the annual value of -$9.7 million for FY2024, which is 56.73% up from last year.
  • As of FY2024, Zevra Therapeutics' Net Cash Flow stood at -$9.7 million, which was up 56.73% from -$22.5 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Net Cash Flow registered a high of $108.0 million during FY2021, and its lowest value of -$47.1 million during FY2022.
  • Its 3-year average for Net Cash Flow is -$26.4 million, with a median of -$22.5 million in 2023.
  • As far as peak fluctuations go, Zevra Therapeutics' Net Cash Flow surged by 13,983.96% in 2021, and later plummeted by 143.59% in 2022.
  • Over the past 5 years, Zevra Therapeutics' Net Cash Flow (Yearly) stood at $767,000 in 2020, then soared by 13,983.96% to $108.0 million in 2021, then crashed by 143.59% to -$47.1 million in 2022, then spiked by 52.30% to -$22.5 million in 2023, then spiked by 56.73% to -$9.7 million in 2024.